02.08.2023 16:32:38
|
Teva Rises On Improved Quarterly Results, Outlook
(RTTNews) - Shares of Teva Pharmaceutical Industries Limited (TEVA) are rising more than 13% Wednesday morning after reporting second quarter results above analyst' view. The company also raised its full-year revenue outlook.
Excluding one-time items, the company reported earnings of $629 million or $0.56 per share, that beat the average estimate of analysts polled by Thomson-Reuters of $0.52 per share.
Net loss in the second quarter was $863 million or $0.77 per share, wider than $232 million or $0.21 per share last year, mainly due to lower tax benefit.
Revenues in the quarter were $3.878 billion, an increase of 2% from the previous-year quarter. The consensus estimate was for $3.71 billion.
For the full year, Teva now expects revenue in the range of $15.0 billion-$15.4 billion, up from the previous outlook of $14.8 billion-$15.4 billion.
Adjusted EPS for the year is expected between $2.25 and $2.55.
Analysts expect the company to report earnings of $2.27 per share on revenue of $15.02 billion for the period.
TEVA is at $9.40 currently. It has traded in the range of $7.09 - $11.45 in the last 1 year.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)mehr Nachrichten
20.12.24 |
NASDAQ Composite Index-Papier Teva Pharmaceutical Industries-Aktie: So viel Gewinn hätte ein Investment in Teva Pharmaceutical Industries von vor einem Jahr abgeworfen (finanzen.at) | |
18.12.24 |
MÄRKTE USA/Etwas leichter - Teva haussieren dank Medikamentenstudie (Dow Jones) | |
17.12.24 |
NASDAQ-Handel NASDAQ Composite verliert schlussendlich (finanzen.at) | |
17.12.24 |
MÄRKTE USA/Etwas leichter - Teva haussieren dank Medikamentenstudie (Dow Jones) | |
17.12.24 |
Anleger in New York halten sich zurück: NASDAQ Composite zeigt sich am Dienstagnachmittag leichter (finanzen.at) | |
17.12.24 |
MÄRKTE USA/Etwas leichter - Medikamentenstudie beflügelt Teva (Dow Jones) | |
17.12.24 |
Schwacher Handel in New York: NASDAQ Composite mittags mit Abgaben (finanzen.at) | |
17.12.24 |
Börse New York in Rot: NASDAQ Composite zum Start leichter (finanzen.at) |